Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2022-12, Vol.36 (12), p.2917-2921
Hauptverfasser:	Slade, Michael, Martin, Thomas G., Nathwani, Nitya, Fiala, Mark A., Rettig, Michael P., Gao, Feng, Deol, Abhinav, Buadi, Francis K., Kaufman, Jonathan L., Hofmeister, Craig C., Gregory, Tara K., Berdeja, Jesus, Chari, Ajai, Rosko, Ashley, Vij, Ravi
Format:	Artikel
Sprache:	eng
Schlagworte:	13/31 45/23 692/699/1541/1990/804 692/700/1750/1976 692/700/565/1436/99 692/700/565/2319 Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts Cancer Research Critical Care Medicine Cytogenetics Dexamethasone Dexamethasone - therapeutic use Hematology Humans Immunotherapy Intensive Internal Medicine Lenalidomide - therapeutic use Letter Leukemia Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Oncology Steroids Targeted cancer therapy Toxicity Transplantation, Autologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!